LIVZON PHARMAC. GRP H YC1 - Asset Resilience Ratio

Latest as of March 2026: 2.93%

LIVZON PHARMAC. GRP H YC1 (LP6) has an Asset Resilience Ratio of 2.93% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore LIVZON PHARMAC. GRP H YC1 asset portfolio for the complete picture of this company's asset base.

Liquid Assets

€707.99 Million

≈ $827.72 Million USD Cash + Short-term Investments

Total Assets

€24.19 Billion

≈ $28.29 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how LIVZON PHARMAC. GRP H YC1's Asset Resilience Ratio has changed over time. See LP6 net asset quality score to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down LIVZON PHARMAC. GRP H YC1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of LIVZON PHARMAC. GRP H YC1.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€707.99 Million	2.93%
Total Liquid Assets	€707.99 Million	2.93%

Asset Resilience Insights

Limited Liquidity: LIVZON PHARMAC. GRP H YC1 maintains only 2.93% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

LIVZON PHARMAC. GRP H YC1 Industry Peers by Asset Resilience Ratio

Compare LIVZON PHARMAC. GRP H YC1's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Jiangsu Hengrui Medicine Co Ltd SHG:600276	Drug Manufacturers - Specialty & Generic	0.16%
Takeda Pharmaceutical Company Limited F:TKDA	Drug Manufacturers - Specialty & Generic	0.69%
Ajanta Pharma Limited NSE:AJANTPHARM	Drug Manufacturers - Specialty & Generic	14.99%
Kangmei Pharmaceutical Co Ltd SHG:600518	Drug Manufacturers - Specialty & Generic	0.00%
Cronos Group Inc TO:CRON	Drug Manufacturers - Specialty & Generic	69.94%
Guizhou Bailing Group Pharmaceutical Co Ltd SHE:002424	Drug Manufacturers - Specialty & Generic	2.09%
Dezhan HealthCare Co Ltd SHE:000813	Drug Manufacturers - Specialty & Generic	0.15%

Annual Asset Resilience Ratio for LIVZON PHARMAC. GRP H YC1 (2021–2025)

The table below shows the annual Asset Resilience Ratio data for LIVZON PHARMAC. GRP H YC1.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	5.61%	€1.34 Billion ≈ $1.57 Billion	€23.99 Billion ≈ $28.04 Billion	+5.24pp
2024-12-31	0.37%	€89.36 Million ≈ $104.47 Million	€24.46 Billion ≈ $28.59 Billion	+0.04pp
2023-12-31	0.33%	€81.79 Million ≈ $95.62 Million	€25.04 Billion ≈ $29.28 Billion	-0.11pp
2022-12-31	0.43%	€108.09 Million ≈ $126.37 Million	€24.87 Billion ≈ $29.07 Billion	-0.38pp
2021-12-31	0.82%	€182.77 Million ≈ $213.68 Million	€22.37 Billion ≈ $26.16 Billion	--

pp = percentage points

About LIVZON PHARMAC. GRP H YC1

F:LP6 Germany Drug Manufacturers - Specialty & Generic

Market Cap

$995.44 Million

€851.45 Million EUR

Market Cap Rank

#9172 Global

#1153 in Germany

Share Price

€2.84

Change (1 day)

+0.00%

52-Week Range

€2.80 - €4.30

All Time High

€4.30